Chemoinformaics analysis of (-)-VINCADIFFORMINE
| Molecular Weight | 338.451 | nRot | 2 |
| Heavy Atom Molecular Weight | 312.243 | nRig | 24 |
| Exact Molecular Weight | 338.199 | nRing | 5 |
| Solubility: LogS | -3.935 | nHRing | 3 |
| Solubility: LogP | 3.017 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 51 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 25 | No. of Aromatic Carbocycles | 1 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 21 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 6 |
| nHA | 4 | APOL | 56.2106 |
| nHD | 1 | BPOL | 30.9674 |
| QED | 0.776 |
| Synth | 4.769 |
| Natural Product Likeliness | 1.664 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.105 |
| Pgp-sub | 0.164 |
| HIA | 0.003 |
| CACO-2 | -4.86 |
| MDCK | 0.0000224 |
| BBB | 0.988 |
| PPB | 0.468923 |
| VDSS | 3.524 |
| FU | 0.603721 |
| CYP1A2-inh | 0.052 |
| CYP1A2-sub | 0.712 |
| CYP2c19-inh | 0.056 |
| CYP2c19-sub | 0.954 |
| CYP2c9-inh | 0.057 |
| CYP2c9-sub | 0.171 |
| CYP2d6-inh | 0.933 |
| CYP2d6-sub | 0.879 |
| CYP3a4-inh | 0.815 |
| CYP3a4-sub | 0.767 |
| CL | 6.081 |
| T12 | 0.118 |
| hERG | 0.38 |
| Ames | 0.035 |
| ROA | 0.883 |
| SkinSen | 0.048 |
| Carcinogencity | 0.716 |
| EI | 0.016 |
| Respiratory | 0.941 |
| NR-Aromatase | 0.877 |
| Antiviral | No |
| Prediction | 0.67698 |